Email Medtest DX Medtest Headquarters Medtest Facebook Medtest Linkedin

Buprenorphine (Suboxone)


(Assays)

METHOD

CEDIA Urine Drug Screening

TECHNICAL INFORMATION

Format: Requires Reconstitution
Wavelength: 578 nm
Linearity: 75 ng/mL
Storage Temperature: 2 - 8° C

Disclaimer: For Use With the Mindray™ BS-200

  • Description
  • Ordering Information
  • Related Products
  • Documentation

Intended Use

The CEDIA Buprenorphine Assay is a homogenous enzyme immunoassay for qualitative or semi-quantitative determination of the presence of buprenorphine in human urine at cutoff concentration of 5 ng/mL. The assay provides a simple and rapid analytical screening procedure to detect buprenorphine in human urine.

Principle

In the assay, analyte in the sample competes with analyte conjugated to one inactive fragment (enzyme donor) of β-galactosidase for a limited number of antibody binding sites. If analyte is present in the sample, it binds to antibody, leaving the inactive enzyme fragment free to form active enzyme. If the analyte is not present in the sample, antibody binds to analyte conjugated on the inactive fragment, inhibiting the re-association of inactive β-galactosidase fragments, and no active enzyme is formed. The amount of active enzyme formed and resultant absorbance change are directly proportional to the amount of analyte present in the sample.